Logo

Congress Data: ASCO & EHA 2022

MRD: The new standard

clonoSEQ is:

  • The most sensitive FDA-cleared MRD Assay for multiple myeloma, CLL, and ALL
  • CLIA-validated in other lymphoid malignancies
  • Reimbursed by Medicare and major private payers for multiple myeloma, CLL, and ALL
  • Clinically used in all 32 NCCN® Member Institutions
  • Included in clinical practice guidelines for multiple myeloma, CLL, and ALL
  • Supported by a significant and expanding body of evidence
  • Featured in >10 abstracts at the ASCO and EHA congresses
  • Widely used, having been performed on >22,000 unique patients to date

For information on ordering clonoSEQ, call us at (888) 552-8988.

ASCO Abstracts

Poster

closeB-PRISM (Precision Intervention Smoldering Myeloma): A phase II trial of combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma.

Omar Nadeem, et al.

View

Poster

Molecular disease monitoring in patients with relapsed/refractory B-cell non-Hodgkin lymphoma receiving anti-CD19 CAR T-cell therapy

Meryl Colton, et al.

View

Poster

Minimal residual disease comparison between Ig/TCR PCR versus NGS assays in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: A report from the COG AALL1631 study

Thai Hoa Tran, et al.

View

Oral

Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma

Matthew Frigault, et al.

View

Poster

Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN

Cesar Rodriguez, et al.

View

Poster

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A

Hermann Einsele, et al.

View

Poster

Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI

Saad Usmani, et al.

View

Poster

Three-year follow-up of outcomes with KTE-X19 in patients with relapsed/refractory mantle cell lymphoma in ZUMA-2

Michael Wang, et al.

View

Poster

Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1

Andrzej Jakubowiak, et al.

View

EHA Abstracts

Oral

LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION

Nitin Jain, et al.

View

Poster

MRD BY MASS SPECTROMETRY IN PERIPHERAL BLOOD AND NEXT GENERATION SEQUENCING IN BONE MARROW IN A PHASE 2 STUDY OF DARATUMUMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE FOR MULTIPLE MYELOMA

Ben Derman, et al.

View

Poster

DOSE-ADJUSTED EPOCH + INOTUZUMAB OZOGAMICIN (DA-EPOCH-INO) IS SAFE AND ACTIVE IN ADULTS WITH RELAPSED/REFRACTORY (R/R) B LYMPHOBLASTIC LEUKEMIA (B-ALL): INITIAL RESULTS OF A PHASE I TRIAL

Ryan Cassaday, et al.

View

Oral

VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION: 6-YEAR FOLLOW-UP AND GENOMIC ANALYSES IN A PIVOTAL PHASE 2 TRIAL

Stephan Stilgenbauer, et al.

View

Oral

VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

Othman Al-Sawaf, et al.

View

Oral

TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB

Othman Al-Sawaf, et al.

View

Oral

CARTITUDE-2 COHORT B: UPDATED CLINICAL DATA AND BIOLOGICAL CORRELATIVE ANALYSES OF CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY

Mounzer Agha, et al.

View

Poster

CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY

Yi Lin, et al.

View

Poster

CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA

Jens Hillengass, et al.

View

Poster

DARATUMUMAB (D) IN COMBINATION WITH VD OR D-RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAPSE AFTER INITIAL THERAPY

Andrew Spencer, et al.

View

Discover clinicians’ real-world experience with clonoSEQ MRD testing

View cases, videos, patient perspectives and more, which illustrate how MRD testing by clonoSEQ may inform clinical decision-making.

Real-World Experience Data

clonoSEQ Product Resources

Learn more about clonoSEQ Assay by downloading these helpful resources:

  • clonoSEQ key publications
  • Talking to your patients about clonoSEQ results
  • HCP Brochure
  • clonoSEQ insurance coverage summary
  • clonoSEQ one-page overview
  • Clinical data summary: CLL MM ALL
  • clonoSEQ clinical reports one pager
  • Adaptive Assist patient support program overview

Connect with Medical Affairs

Request information from a member of our Medical Affairs team.

Adaptive Immune Medicine Platform

Learn how the platform applies our proprietary technologies, computational biology, software and machine learning to read the diverse genetic code of a patient’s immune system and understand precisely how it detects and treats disease in that patient.

Twitter feed Follow us


This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). CLL Clonality (ID) Tests will also produce an IGHV status result, which is provided as a CLIA-validated laboratory developed test (LDT) but which has not been cleared or approved by the FDA. Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.